Whalesbook
Court Rules on Advanced Drug Pricing
The Bombay High Court's recent judgment exempts specific advanced drug delivery systems from price ceilings set by the National Pharmaceutical Pricing Authority (NPPA). This ruling, which challenges NPPA's interpretations of the Drugs (Price Control) Order, 2013 (DPCO 2013), focuses on which formulations are subject to mandated price controls. While the pharmaceutical industry sees this as recognition for innovation, it intensifies the discussion on how to maintain affordable and accessible medicines in India.
Exemption Details for SR/CR Formulations
The High Court's order on April 10, 2026, clarified that price ceilings under DPCO 2013 apply only to formulations explicitly named in the order's First Schedule. Consequently, advanced systems such as sustained-release (SR) and controlled-release (CR) versions are now exempt from NPPA price regulations, provided they are not specifically listed. This exemption provides significant relief to companies like Franco Indian Pharmaceuticals, a privately held firm with reported FY25 revenues of ₹1,020 Cr. As an unlisted entity, Franco Indian Pharmaceuticals does not have readily available market data like stock prices or P/E ratios. Broader market reaction is likely to be seen in sector-wide movements reflecting investor sentiment on regulatory clarity versus potential changes in profit margins.
Industry's Call for Pricing Flexibility
This judicial decision supports a long-standing industry request for greater flexibility in pricing innovative dosage forms. Pharmaceutical associations have argued that SR, CR, and modified-release (MR) formulations offer distinct therapeutic advantages that justify different pricing than standard medicines. The DPCO 2013 itself aimed to improve access by shifting from cost-based to market-based pricing, setting prices based on average market rates. However, the current debate hinges on interpreting 'scheduled formulations' and whether new delivery systems for drugs on the National List of Essential Medicines (NLEM) automatically fall under price control.
Historical Context and Market Impact
Historically, India's price control policies have sought to balance affordability with the need for pharmaceutical companies to operate sustainably. While annual price adjustments for NLEM drugs are linked to WPI, and non-scheduled drugs have a 10% annual cap, excluding specific advanced formulations from direct price limits creates a market-driven pricing segment. Previous studies on price controls in India indicated that companies sometimes shifted focus to unregulated medications due to lower profit margins on controlled ones. This ruling could potentially encourage similar shifts, impacting overall drug affordability, especially for lower-income groups.
Concerns Over Affordability and Access
Public health advocates have expressed significant concern over the judgment. K.M. Gopakumar, co-convenor at the Working Group on Access to Medicines and Treatment, stated that the ruling reveals potential loopholes in DPCO 2013. The worry is that well-resourced companies might use this exemption to develop new variants of essential medicines, effectively sidestepping price controls. This could lead to a tiered pricing system where advanced formulations remain much more expensive, creating barriers for patients needing improved drug delivery but unable to afford the higher cost. The NPPA faces the task of ensuring this regulatory ambiguity does not compromise the goal of accessible essential medicines for everyone. Unlike public companies, Franco Indian Pharmaceuticals' private status offers less transparency on its specific pricing strategies for these advanced products.
Government's Next Steps
The court's decision highlights the need for the government to address potential regulatory gaps. There is a growing view that amendments to DPCO 2013 may be necessary to ensure all NLEM-listed molecules are effectively price-controlled, regardless of their delivery system. The government's continued efforts to expand the NLEM and strengthen drug price regulations indicate a commitment to affordability. However, finding a way to regulate advanced, non-scheduled formulations without hindering innovation presents a complex challenge that will shape pharmaceutical pricing and access in India.